Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity

• Published in: Korean journal of ophthalmology Vol. 28; no. 6; pp. 466 - 472
• Main Authors: Chang, Young Suk, Han, Jung Il, Yoo, Su Jin, Lew, Young Ju, Kim, Jae Hui
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Ophthalmological Society 01.12.2014; 대한안과학회
• Subjects: Aged; Angiogenesis Inhibitors - therapeutic use; Bevacizumab - therapeutic use; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - physiopathology; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Middle Aged; Original; Ranibizumab - therapeutic use; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - physiopathology; 안과학; Macular degeneration; Anti-vascular endothelial growth factor; Good visual acuity; Ranibizumab; Bevacizumab
• ISSN: 1011-8942; 2092-9382; 2092-9382
• DOI: 10.3341/kjo.2014.28.6.466

To investigate 12-month treatment outcomes of anti-vascular endothelial growth factor therapy in eyes with typical exudative age-related macular degeneration with good baseline visual acuity. This retrospective observational case series included 18 eyes (18 patients) with typical exudative age-related macular degeneration with a baseline best-corrected visual acuity of 20 / 25 or better. Patients were treated with anti-vascular endothelial growth factor monotherapy during the 12-month follow-up period. Baseline visual acuity and central foveal thickness were compared to the values at 12 months. Patients received an average of 4.4 ± 1.3 intravitreal anti-vascular endothelial growth factor injections. The mean logarithm of minimum angle of resolution visual acuity was 0.08 ± 0.04, 0.08 ± 0.07, 0.12 ± 0.09, and 0.16 ± 0.11 at baseline, three months, six months, and 12 months, respectively. Visual acuity at 12 months was significantly worse than the baseline value at diagnosis (p = 0.017), and the mean central foveal thickness at the defined time points was 270.2 ± 55.6, 204.4 ± 25.4, 230.1 ± 56.3, and 216.8 ± 48.7 µm, respectively. The central foveal thickness at 12 months was significantly less than the baseline value at diagnosis (p = 0.042). Deterioration in visual acuity was noted in eyes with typical exudative age-related macular degeneration with good baseline visual acuity, suggesting the need for close patient monitoring and prompt treatment even in patients with good baseline visual acuity.